These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Hansen CR; Pressler T; Høiby N J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078 [TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
17. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
18. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Pier GB Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760 [TBL] [Abstract][Full Text] [Related]
19. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum. Schiller NL; Millard RL Pediatr Res; 1983 Sep; 17(9):747-52. PubMed ID: 6413945 [TBL] [Abstract][Full Text] [Related]
20. Effects of mucoid and non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients on inflammatory mediator release from human polymorphonuclear granulocytes and rat mast cells. Friedl P; König B; König W Immunology; 1992 May; 76(1):86-94. PubMed ID: 1321094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]